Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report

• DOI: 10.3892/mco.2017.1519
• Publication Date: 2017-11-27T12:13:54Z
• Authors: Rammohan Prasanna; Deepak Bunger; Mujtaba Khan
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

The standard of care for locally advanced cervical cancer has been the combination of a taxane with platinum based therapy. Conventional docetaxel is known to cause hypersensitivity reactions, fluid retention and other toxicities due to polysorbate-80 and ethanol. Corticosteroid premedication prior to docetaxel administration is required to prevent these toxicities, however, toxicities are still observed, sometimes fatal, despite premedication. DoceAqualip, a nanosomal docetaxel lipid suspension, developed with lipids generally regarded as safe (GRAS) by the US Food and Drug Administration, is devoid of polysorbate-80 and ethanol. DoceAqualip has been demonstrated to be effective and well-tolerated in various cancer types. The authors' report a case of a patient with Stage IIIB cervical cancer who was treated with carboplatin and DoceAqualip (concurrent ChemoRT) and achieved complete response without any serious adverse events.